455 completed, 81 terminated, 58 unknown, 46 recruiting. 715 Phase 3, 84 Phase 2.
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease | Phase 3 | Withdrawn | Vertex Pharmaceuticals Incorporated | 2027-07-31 | 2026-03-25 | |
| A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) Roxadustat, Placebo - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Kyntra Bio | 201 | 2027-04-01 | 2026-07-23 |
| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. FXS6837 Capsule, Eculizumab infusion - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 90 | 2026-12-10 | 2026-08-05 |
| A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®] - Iron Deficiency Anemia (IDA) | Phase 3 | Not yet recruiting | AFT Pharmaceuticals, Ltd. | 1366 | 2026-12-01 | 2026-08-20 |
| A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy VSA012, Eculizumab (Soliris®) - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Not yet recruiting | Bisirna Therapeutics (Suzhou) Co., Ltd. | 70 | 2026-10-29 | 2026-09-11 |
| Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia Thalidomide, Danazol, Prednisolone - Beta-Thalassemia, Thalassemia | Phase 3 | Recruiting | Khyber Medical University Peshawar | 172 | 2026-10-12 | 2026-10-21 |
| Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients N-acetylcysteine - Aplastic Anemia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 142 | 2026-09-30 | 2026-09-16 |
| Nutritional Optimization in Anemic Patients Scheduled for Elective Open-Heart Surgery Immune Modulating Formula, Whey Protein, Multivitamins and Iron Supplements - Anemia, Iron Deficiency | Phase 3 | Not yet recruiting | National Institute of Cardiovascular Diseases, Pakistan | 140 | 2026-09-10 | 2026-09-03 |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-10-01 |
| Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease Iloprost, Placebo - Vaso-Occlusive Crises, Sickle Cell Disease | Phase 3 | Not yet recruiting | University Hospital, Rouen | 144 | 2026-09-01 | 2026-03-27 |
| Tranexamic Acid for Anaemia Trial Tranexamic Acid 500 MG, Placebo - Anaemia | Phase 3 | Recruiting | London School of Hygiene and Tropical Medicine | 4000 | 2026-08-10 | 2026-08-17 |
| A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment Avatrombopag 20 mg Oral Tablet - Aplastic Anemia | Phase 2 / Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 26 | 2026-07-31 | 2026-08-26 |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Mitapivat Matched Placebo, Mitapivat - Sickle Cell Disease | Phase 3 | Recruiting | Agios Pharmaceuticals, Inc. | 159 | 2026-07-21 | 2026-10-28 |
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| How Precision Diets, Through Gut Bacteria, Affect Anemia in Nepalese Adolescent Iron folic acid supplement, Goat liver supplementation, Nutrition education on anemia prevention and control - Anemia | Phase 3 | Not yet recruiting | Southern Medical University, China | 60 | 2026-07-01 | 2026-06-25 |
| A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 35 | 2026-06-11 | 2026-08-05 |
| A Long-term Efficacy and Safety of NTQ5082 Capsules NTQ5082 capsules 200 mg - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 78 | 2026-06-01 | 2025-09-17 |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Elritercept, Epoetin Alfa - Myelodysplastic Syndrome, Anemia | Phase 3 | Recruiting | Takeda | 300 | 2026-05-21 | 2026-10-19 |
Showing 20 of 715. Sign in to see all of them.
Anemia, Sickle Cell (107) · Anemia, Iron-Deficiency (91) · Renal Insufficiency, Chronic (79) · Hemoglobinuria, Paroxysmal (49) · Myelodysplastic Syndromes (44) · Iron Deficiencies (32) · beta-Thalassemia (32) · Anemia, Refractory, with Excess of Blasts (30) · Hematologic Diseases (30) · Leukemia (26) · Vaso-Occlusive Crises (26) · Neoplasms (25) · Anemia, Aplastic (24) · Kidney Failure, Chronic (19)
Hemic and Lymphatic Diseases (715) · Hematologic Diseases (685) · Anemia, Hemolytic (222) · Pathological Conditions, Signs and Symptoms (181) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (174) · Pathologic Processes (158) · Anemia, Hemolytic, Congenital (154) · Genetic Diseases, Inborn (153) · Hemoglobinopathies (139) · Nutritional and Metabolic Diseases (132) · Bone Marrow Diseases (129) · Disease Attributes (125) · Metabolic Diseases (125) · Urogenital Diseases (124)
Epoetin Alfa (65) · Darbepoetin alfa (61) · ferric carboxymaltose (44) · continuous erythropoietin receptor activator (42) · ferrous sulfate (29) · Iron (27) · eculizumab (26) · Ferric Oxide, Saccharated (23) · Hydroxyurea (19) · Iron-Dextran Complex (19) · roxadustat (18) · Cyclophosphamide (16) · Ferrosoferric Oxide (15) · Erythropoietin (14) · iron isomaltoside 1000 (14)
Hoffmann-La Roche (48) · Amgen (28) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (21) · American Regent, Inc. (20) · Novartis Pharmaceuticals (15) · Alexion Pharmaceuticals, Inc. (14) · Pharmacosmos A/S (14) · AMAG Pharmaceuticals, Inc. (13) · Assistance Publique - Hôpitaux de Paris (13) · Pfizer (12) · GlaxoSmithKline (10) · London School of Hygiene and Tropical Medicine (10) · Ain Shams University (9) · Akebia Therapeutics (9) · Kyntra Bio (9)
United States (272) · France (128) · United Kingdom (124) · Italy (118) · Germany (117) · Canada (104) · Spain (97) · Poland (71) · Brazil (70) · Belgium (64) · Australia (58) · Japan (58) · Netherlands (56) · Turkey (Türkiye) (55) · Czechia (51)
Vice President, Clinical Development (4)
PMID 36005278, PMID 36791280, PMID 26965694, PMID 34932836, PMID 41114449, PMID 37975597, PMID 23343061, PMID 23343062, PMID 36749544, PMID 37254256, PMID 38363466, PMID 40359056, PMID 20175775, PMID 31203241, PMID 33783815, PMID 34219224, PMID 34362786, PMID 38780066, PMID 39535306, PMID 40277027, PMID 40694294, PMID 16710026, PMID 17634466, PMID 17666600, PMID 18227526, PMID 19721013, PMID 19920054, PMID 20940381, PMID 22874106, PMID 25545376, PMID 27237709, PMID 30952488, PMID 31203242, PMID 31974203, PMID 32016310, PMID 33275766, PMID 33283989, PMID 33439748, PMID 33913637, PMID 33913638, PMID 34175041, PMID 34526067, PMID 35981565, PMID 36565721, PMID 36594181, PMID 37095342, PMID 37096396, PMID 37651553, PMID 38383961, PMID 38477987
2023 (11), 2016 (10), 2017 (9), 2019 (9), 2005 (5), U10CA021115 (5), 2008 (4), 2015 (4), 2014 (3), U10CA180820 (3), 2009 (2), 2025 (2), U24CA196172 (2), 1RC2HL101458-01 (1), 1UG3HL157564-01A1 (1)